NEW YORK (GenomeWeb News) – ILS and Stemina Biomarker Discovery today announced they will work together to advance Stemina's stem cell-based toxicology testing platform, beginning with devTOX, an all-human based screen for evaluating the toxicity of drugs and chemical compounds on human development.
The deal gives ILS exclusive rights to distribute Stemina's platform in North America. The firms will also collaborate on the development of other platforms for evaluating the safety of compounds, they said.
Financial terms of the deal were not disclosed.
DevTox is a metabolomics platform that uses human embryonic stem cells to analyze the effects that pharmaceuticals, chemicals, and formulations may have on embryos.
Based in Research Triangle Park, NC, ILS is a research organization that provides support to the toxicology, genetic and molecular, histopathology, environmental, and information science fields.
Madison, Wis.-based Stemina uses mass spectrometry-based metabolomics to analyze small molecules secreted by cells in response to drugs, chemical compounds, and other contaminants.